CJC-1295 + Ipamorelin

GHRH analogue + selective secretagogue · Growth · Recovery · Sleep

The most common growth-hormone stack in circulation — accelerator and brake-release together.

Form: 10 mg — pre-reconstituted in the Cellvéra injector
Oversight: Licensed clinician, included
Price: From R3 713 / protocol

For research purposes only · Not for human consumption

Begin your intake

Opens a private email to our concierge · nothing is charged

Checkout begins your confidential medical intake. CJC-1295 + Ipamorelin is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.

Pathway

A pre-combined blend of short-acting CJC-1295 (no DAC) with ipamorelin in a single preparation.

Mechanism

The logic of the pairing is that the two act on different receptors: the GHRH analogue tells the pituitary to release growth hormone, while the secretagogue simultaneously suppresses somatostatin, the brake on that release. Pressing the accelerator and lifting the brake together produces a larger pulse than either alone.

Studied for

The most common growth-hormone "stack" in circulation
Recovery, sleep and body composition

Areas of research interest — not promised outcomes.

Where the evidence stands

The synergy between GHRH analogues and secretagogues is a real, documented pharmacological principle. The specific blend, as sold, has no clinical trial behind it.

Typical protocol

Dosing is individualised and set by your supervising clinician at intake. Published human dosing for this compound is not established; conservative titration and monitoring are part of every protocol.

Contraindications & cautions

Combines two unapproved research compounds — the individual notes for each apply in full. Active malignancy. Growth-hormone pathway compounds are prohibited in sport (WADA). Effects on blood sugar should be considered. Pregnancy or breastfeeding.

Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.

Important safety information

CJC-1295 + Ipamorelin is dispensed as a compounded preparation under valid prescription only. Compounded medications are not FDA-evaluated for safety or efficacy. Report adverse events to your supervising clinician immediately. Keep refrigerated; keep out of reach of children.

Discussed at consultation

Your clinician may recommend an alternative or a staged protocol.

BPC-157 From R2 912 · View → BPC-157 + TB-500 From R3 978 · View →